ISLAMABAD: Pakistan’s pharmaceutical industry is approaching a major regulatory deadline as the Drug Regulatory Authority of Pakistan (DRAP) moves to make serialized 2D barcodes mandatory on applicable medicine packs from October 9, 2026, marking a significant step towards digitally tracking medicines through the country’s supply chain.
The requirement flows from S.R.O. 963(I)/2026, issued on June 9, 2026, under amendments to the Drugs (Labelling and Packing) Rules, 1986. The framework gives the industry four months to implement GS1 DataMatrix barcoding and serialization at the relevant saleable-pack level, placing the first major compliance milestone on October 9.
The development follows the Federal Cabinet’s approval on June 2, 2026 of a nationwide pharmaceutical Track & Trace System. The Federal Ministry for National Health Services, Regulations and Coordination said at the time that the initiative was intended to tackle counterfeit, fake and substandard medicines by allowing pharmaceutical products to be digitally identified and verified throughout the supply chain.
What will medicine packs actually carry?
Under the new framework, applicable secondary medicine packaging will carry a GS1 DataMatrix, a machine-readable two-dimensional barcode containing key product identifiers.
The required data include a Global Trade Item Number (GTIN), batch or lot number, expiry date and a unique serialized number assigned to the individual saleable pack. DRAP’s regulatory framework specifically provides for randomized serialization within the GS1 DataMatrix.
This is more specific than simply placing a conventional barcode or QR code on a medicine carton. The regulatory model is based on GS1 pharmaceutical identification standards, allowing individual packs to be distinguished from other packs of the same medicine and batch.
Where a medicine is sold directly in its primary packaging without a secondary carton or other secondary pack, barcode labelling becomes applicable to that primary packaging instead.
That distinction is important for both manufacturers and consumers: the October requirement is not simply about putting the same product barcode on thousands of boxes. Serialization means individual packs receive unique identities.
Imported medicines are covered too
The framework also addresses products entering Pakistan from overseas.
Where an imported drug does not already meet the prescribed barcode requirement at the time of import, the importer may arrange compliant GS1 DataMatrix printing at an appropriately licensed local facility, subject to approval by the Registration Board, before the medicine is placed on the market.
The provision means the transition is not confined to domestic pharmaceutical production lines; importers also have compliance responsibilities.
Which medicines are affected?
The serialization framework applies to allopathic medicines, including biological products for human and veterinary use, according to analyses of the finalized regulatory requirements. It should therefore not be described simply as applying to every therapeutic product regulated by DRAP.
Categories such as alternative medicines, nutraceuticals, medical devices, medical gases and radiopharmaceuticals are outside the stated pharmaceutical serialization scope described for S.R.O. 963(I)/2026.
This distinction matters because reports saying “all medicines and all DRAP products” will require identical serialization can overstate the reach of the regulation.
A national digital Track & Trace platform is being built
The barcode requirement is only one component of a much larger digital infrastructure project.
On June 10, 2026, the National Information Technology Board (NITB) and DRAP signed a memorandum of understanding to jointly design, develop, deploy, integrate, operationalize and host a National Pharmaceutical Products Track & Trace System.
NITB says the platform is being developed to provide traceability, product authentication, regulatory oversight, end-to-end visibility and real-time monitoring of pharmaceutical products across the supply chain, with the broader objective of combating counterfeit, substandard and unregistered medicines.
DRAP’s existing Drug Regulatory Information System also describes the policy objective as creating a government-controlled pharmaceutical database capable of tracing products through GS1 2D DataMatrix identifiers.
But there is an important qualification.
The October 9 deadline is a major serialization milestone, but it should not be confused with the completion of Pakistan’s entire end-to-end Track & Trace architecture.
The regulations provide a considerably longer transition for tertiary or logistics packaging.
For higher-level shipping units, the framework provides for GS1-128 barcodes and Serial Shipping Container Codes (SSCCs), but makes the tertiary-pack SSCC requirement mandatory only after a six-year transition period. Based on the June 9, 2026 commencement, that points to June 9, 2032 for this phase.
This means the industry is facing two different milestones:
October 9, 2026: GS1 DataMatrix and serialization at the applicable saleable pack level.
June 9, 2032: mandatory SSCC requirements for tertiary logistics units under the phased framework.
For patients and industry observers, the distinction is significant. The first phase gives medicines individual digital identities; the later logistics layer is intended to strengthen how those identities are associated with larger shipping and distribution units.
Why the new system matters for patients
The government says the eventual nationwide platform is intended to make it substantially harder for counterfeit and unregistered medicines to move unnoticed through legitimate distribution channels.
That consumer-facing capability, however, should be understood as part of the broader Track & Trace rollout rather than an assurance that every feature will automatically become available nationwide on October 9.
The immediate regulatory shift is more fundamental: manufacturers and importers will increasingly have to associate medicine packs with standardized digital identifiers that can be captured and checked electronically.
What pharmaceutical manufacturers now have to prepare for
For manufacturers, serialization is not simply a packaging artwork change.
Companies may need to align product master data, obtain and manage appropriate GS1 identifiers, generate unique serial numbers, install or configure printing systems, verify DataMatrix readability, connect inspection systems with production lines and prepare their software infrastructure for regulatory data exchange.
DRAP has been moving toward implementation for some time. In August 2025, the regulator had already directed the pharmaceutical industry to provide information needed for implementation of 2D barcodes and serialization, indicating that technical preparation predates the final 2026 framework.
More recently, industry capacity-building and technical-awareness sessions have focused on serialization, GS1 DataMatrix requirements, data workflows and production readiness as manufacturers work towards the October milestone.
Does every medicine without a barcode become illegal to sell on October 9?
That interpretation needs caution.
The regulatory requirement clearly creates compliance obligations for applicable pharmaceutical packaging and requires non-compliant imported medicines to be brought into conformity before market release.
However, the regulatory material reviewed for this report does not establish that every previously manufactured, legitimately released pack already sitting in Pakistan’s supply chain automatically becomes prohibited for retail sale at midnight on October 9.
A blanket statement that “all medicines without barcodes will be banned from the market after the deadline” therefore goes beyond what the cited provisions establish unless DRAP separately issues stock-transition or enforcement instructions dealing specifically with legacy inventory.
For manufacturers and distributors, the safer regulatory interpretation is that the October 9 compliance requirement should be treated as a firm production and market-release milestone, while any treatment of previously released inventory should follow DRAP’s specific enforcement instructions.
Pakistan's pharma sector is entering a much bigger transition
For pharmaceutical manufacturers, importers, distributors and technology suppliers, October 9 is therefore less an endpoint than the beginning of a wider transformation.
The immediate requirement is focused on identity and serialization at pack level. What follows is the construction of the digital reporting, verification and logistics infrastructure needed to carry those identities through an increasingly connected pharmaceutical supply chain.
If implemented as planned, Pakistan’s system could eventually allow regulators to reconstruct where medicines originated, identify suspicious products more quickly, support targeted recalls and improve authentication across formal distribution channels — capabilities that become more powerful as additional stages of Track & Trace are brought online.
For the industry, however, the nearest date is now clear: October 9, 2026.
And for companies still treating pharmaceutical serialization as a future project, that deadline is now only weeks away.
Stay connected with Medical News Pakistan
CLICK HERE TO JOIN the official Medical News Pakistan WhatsApp Channel for verified global medical breakthroughs, FDA approvals, healthcare innovations, clinical research updates and the latest developments shaping medicine around the world.